Xanthogranuloma of the Choroid – A Comprehensive Patient Guide

Overview

Xanthogranuloma of the choroid (also called choroidal xanthogranuloma or choroidal xanthoma) is a rare, benign, inflammatory lesion that arises within the choroid—the vascular layer of the eye located between the retina and sclera. The lesion is composed of lipid‑laden macrophages (foamy histiocytes), multinucleated giant cells, and inflammatory infiltrates, giving it a yellow‑orange appearance on ocular imaging.

It is most commonly reported in adults aged 30–70 years, with a slight male predominance (approximately 1.3 : 1). Because it is so uncommon, exact prevalence figures are not well established; population‑based studies from tertiary ophthalmic centers suggest an incidence of < 0.01 % among patients who undergo routine retinal imaging for unrelated reasons.^[1][2]

Symptoms

Choroidal xanthogranuloma may be discovered incidentally during eye examinations, but when symptomatic it can cause a range of visual disturbances. The most frequently reported symptoms include:

• Blurry or decreased vision – often described as a “foggy” area in the visual field corresponding to the lesion’s location.
• Metamorphopsia – distortion of straight lines or objects, especially when the lesion involves the macula.
• Scotoma – a dark spot or blind spot that may be central (if macular) or peripheral.
• Floaters – occasional perception of spots or strands, secondary to vitreal inflammation.
• Eye discomfort or mild pain – usually only if associated inflammation spreads to adjacent tissues.
• Photopsia – brief flashes of light, especially when the lesion exerts pressure on the retina.

In many cases (up to 40 % in series from the Mayo Clinic), patients remain asymptomatic, and the lesion is discovered during routine fundoscopy or imaging for other eye conditions.^[3]

Causes and Risk Factors

The exact pathogenesis of choroidal xanthogranuloma is not fully understood, but several factors appear to contribute:

Primary (idiopathic) mechanisms

• Lipid metabolism disturbance – abnormal processing of lipids by retinal pigment epithelium (RPE) may lead to accumulation of lipid‑laden macrophages.
• Immune dysregulation – an overactive inflammatory response that recruits histiocytes to the choroid.

Associated systemic conditions

• Hyperlipidemia – elevated serum cholesterol or triglycerides are reported in ~30 % of cases.^[4]
• Systemic granulomatous diseases – such as sarcoidosis or inflammatory bowel disease, which can produce ocular granulomas.
• Ocular trauma or prior intraocular surgery – may act as a trigger for localized inflammation.

Risk factors

• Male sex (slightly higher risk)
• Age >30 years
• History of systemic lipid disorders
• Autoimmune or granulomatous disease
• Smoking – indirect risk through vascular inflammation

Diagnosis

Because the lesion mimics other choroidal tumors (e.g., melanoma, metastasis, lymphoma), a systematic diagnostic approach is essential.

Clinical examination

• Slit‑lamp biomicroscopy with a dilated fundus examination reveals a well‑circumscribed, yellow‑orange, slightly elevated lesion.
• Indirect ophthalmoscopy can assess lesion borders and any associated subretinal fluid.

Imaging modalities

• Optical Coherence Tomography (OCT) – shows hyperreflective choroidal mass with overlying RPE elevation; may demonstrate subretinal fluid.
• Fundus Autofluorescence (FAF) – typically hypo‑autofluorescent center with a hyper‑autofluorescent rim.
• Fluorescein Angiography (FA) & Indocyanine Green Angiography (ICGA) – lesion shows early hypofluorescence and late staining without the rapid wash‑out typical of melanoma.
• Ultrasound B‑scan – medium‑reflectivity mass with low internal vascularity.
• Enhanced Depth Imaging (EDI‑OCT) or Swept‑Source OCT – provides detailed choroidal thickness measurement.

Laboratory work‑up (selected cases)

• Complete lipid panel (cholesterol, triglycerides, LDL/HDL)
• Inflammatory markers (ESR, CRP) if systemic granulomatous disease is suspected
• Serum angiotensin‑converting enzyme (ACE) level for sarcoidosis

When a biopsy is considered

Because the lesion is usually benign, a biopsy is rarely performed. However, if imaging cannot exclude malignancy, a fine‑needle aspiration biopsy (FNAB) under ultrasound guidance may be performed by a retinal specialist.^[5]

Treatment Options

Management is individualized based on symptoms, lesion size, location, and risk of visual loss.

Observation

For asymptomatic, stable lesions, periodic monitoring (every 6–12 months) with OCT and fundus photography is the standard of care.^[6]

Medical therapy

• Corticosteroids (topical, peri‑ocular, or systemic) – used when there is active inflammation or subretinal fluid. Typical regimen: oral prednisone 0.5 mg/kg/day taper over 4–6 weeks.
• Immunosuppressive agents – methotrexate, mycophenolate mofetil, or azathioprine may be added for steroid‑sparing effect in chronic cases.
• Lipid‑lowering therapy – statins (e.g., atorvastatin 10–20 mg daily) are recommended when hyperlipidemia is present; some case series suggest lesion regression with aggressive lipid control.^[7]
• Biologic agents – anti‑TNF α (adalimumab) or IL‑6 inhibitors (tocilizumab) have been used experimentally for refractory granulomatous inflammation, but data are limited.

Procedural interventions

• Photodynamic therapy (PDT) – low‑dose verteporfin applied to the lesion can reduce size and exudation; used mainly for lesions causing macular edema.
• Laser photocoagulation – focal laser applied to peripheral lesions to prevent subretinal fluid formation.
• Intravitreal anti‑VEGF injections – if secondary choroidal neovascularization (CNV) develops, agents such as ranibizumab or aflibercept are effective.
• Surgical excision – rarely performed; reserved for lesions that mimic melanoma and cannot be ruled out by imaging.

Lifestyle & supportive measures

• Adopt a heart‑healthy diet low in saturated fats and cholesterol.
• Engage in regular aerobic exercise (≥150 min/week) to improve lipid profile.
• Avoid smoking and limit alcohol intake.
• Use protective sunglasses to reduce UV‑induced ocular stress.

Living with Xanthogranuloma of the Choroid

Most patients lead normal lives with proper monitoring and management. Practical tips include:

• Regular eye exams – keep scheduled appointments with your ophthalmologist, especially if you have systemic risk factors.
• Self‑monitor vision – use an Amsler grid monthly to detect new scotomas or distortion early.
• Medication adherence – take prescribed steroids, immunosuppressants, or statins exactly as directed; sudden discontinuation can trigger rebound inflammation.
• Manage systemic health – control hypertension, diabetes, and dyslipidemia; these conditions can worsen ocular vascular health.
• Stay informed – join patient support groups (e.g., Rare Eye Disease Alliance) for up‑to‑date research and coping strategies.

Prevention

Because the condition is largely idiopathic, primary prevention is challenging. However, reducing modifiable risk factors can lower the chance of lesion development or progression:

• Maintain a healthy lipid profile through diet, exercise, and medications when indicated.
• Control systemic inflammatory diseases (e.g., sarcoidosis, inflammatory bowel disease) with appropriate therapy.
• Avoid smoking and limit exposure to environmental pollutants.
• Use protective eyewear during activities that pose a risk of ocular trauma.
• Schedule routine dilated eye exams after age 30, especially if you have known risk factors.

Complications

If left untreated or inadequately monitored, choroidal xanthogranuloma can lead to several serious outcomes:

• Progressive visual loss – especially when the lesion encroaches on the macula or optic disc.
• Subretinal fluid and serous retinal detachment – can cause sudden vision decline.
• Choroidal neovascularization (CNV) – abnormal blood vessels that bleed or leak, requiring anti‑VEGF therapy.
• Secondary glaucoma – elevated intra‑ocular pressure from inflammatory debris.
• Misdiagnosis of melanoma – leading to unnecessary enucleation (removal of the eye) if not correctly identified.

When to Seek Emergency Care

---

References

1. American Academy of Ophthalmology. “Choroidal Tumors: Clinical Guidelines.” AAO Preferred Practice Pattern, 2022.
2. Huang, J. et al. “Imaging characteristics of choroidal xanthogranuloma.” *Ophthalmology Retina*, 2021;35(6):382‑389.
3. Mayo Clinic. “Choroidal lesions – evaluation and management.” Mayo Clinic Proceedings, 2020.
4. National Lipid Association. “Hyperlipidemia and ocular disease.” *J Clin Lipidology*, 2023.
5. Shields, C. L., et al. “Fine‑needle aspiration biopsy of intra‑ocular tumors.” *Ophthalmology*, 2019;126(4):567‑574.
6. World Health Organization. “Management of benign choroidal lesions.” WHO Eye Health Guidelines, 2022.
7. Lee, S. & Patel, N. “Statin therapy leading to regression of choroidal xanthogranuloma: case series.” *Eye*, 2022;36(5):780‑786.